The newest treatments for trigeminal neuralgia focus on drugs that target specific sodium channels and pain receptors, moving away from the broad-acting anticonvulsants that have been the standard for decades. Several are in clinical trials now, while others, like botulinum toxin injections and CGRP inhibitors, are already being used off-label with promising early results. The treatment landscape is shifting toward options that aim to block pain signals more precisely, with fewer of the cognitive side effects that make older medications hard to tolerate.
Vixotrigine: A Sodium Channel Blocker in Trials
Vixotrigine is one of the most closely watched drugs in the trigeminal neuralgia pipeline. It works by selectively blocking sodium channels on nerve fibers, but only when those nerves are firing at abnormally high frequencies. In practical terms, this means it targets the overactive nerve signaling that causes trigeminal neuralgia pain while leaving normal nerve function relatively untouched. That selectivity is the key advantage over older medications like carbamazepine and oxcarbazepine, which dampen nerve activity more broadly and often cause drowsiness, dizziness, and difficulty concentrating.
Vixotrigine has completed a Phase II trial showing efficacy for trigeminal neuralgia pain. It was originally developed under the name CNV1014802 before being acquired by Biogen (where it was called BIIB074). The Phase II trial used a randomized withdrawal design: patients first took the drug openly for 21 days, and those who responded were then randomly assigned to continue the drug or switch to placebo for 28 days. This design is particularly suited to rare conditions where recruiting large numbers of patients is difficult. Results showed meaningful pain relief, though the drug has not yet reached Phase III approval.
Basimglurant: A Different Target Entirely
While most new drugs for trigeminal neuralgia go after sodium channels, basimglurant takes a different approach. It blocks a specific glutamate receptor involved in pain amplification. Glutamate is the brain’s main excitatory chemical messenger, and overactivity at this receptor can intensify pain signals. By dialing that activity down, basimglurant may reduce both the sharp electric-shock attacks and the continuous background aching that many patients experience between attacks.
A clinical trial registered on ClinicalTrials.gov is evaluating basimglurant in trigeminal neuralgia patients across three phases: an initial 8-week period measuring changes in pain diary scores and attack frequency, a 12-week phase tracking how long pain relief lasts after treatment, and a 52-week open-label extension assessing long-term safety. The drug has already demonstrated a favorable safety profile in adults, children, and adolescents in other conditions, which is part of why it advanced to trigeminal neuralgia trials. Results are still pending.
CGRP Inhibitors: Borrowed From Migraine Treatment
Drugs originally developed for migraine prevention are showing early promise in trigeminal neuralgia. These medications block calcitonin gene-related peptide (CGRP), a molecule that promotes pain signaling and inflammation in the trigeminal nerve system. CGRP levels are elevated in trigeminal neuralgia patients, which makes these drugs a logical fit even though they weren’t designed for the condition.
In a retrospective study of 10 patients with medication-resistant trigeminal neuralgia treated with erenumab (a monthly injection originally approved for migraine), 9 out of 10 reported improvement in both pain severity and overall mood. Side effects were minimal, limited to constipation and injection site reactions in a few patients. Clinical trials have also been initiated for two other CGRP-targeting drugs, rimegepant and galcanezumab, in trigeminal neuralgia, though results haven’t been published yet.
This is still considered Class IV evidence, the lowest level of clinical certainty, because the study was small and retrospective. But for patients who have failed multiple standard medications, CGRP inhibitors represent a treatment option that some neurologists are already prescribing off-label.
Botulinum Toxin Injections
Botulinum toxin (Botox) injections directly into the painful area of the face have emerged as a treatment for trigeminal neuralgia that doesn’t respond to standard drugs. Unlike its cosmetic use, which targets muscles, the injections for trigeminal neuralgia are placed between the skin layers or under the oral mucosa, specifically avoiding deeper muscle tissue to prevent unwanted weakness in the face.
A randomized, double-blind, placebo-controlled trial tested two doses (25 units and 75 units) against placebo in 84 patients. The toxin was injected at approximately 20 points across the painful region. Both doses provided meaningful relief, and in one documented case, a single treatment with 170 units provided complete pain relief lasting two years. The treatment is considered useful for refractory cases, particularly for patients who are not candidates for surgery or who want to avoid more invasive procedures.
Spinal Cord Stimulation for Refractory Cases
For patients who have exhausted medications and even surgical options, cervical spinal cord stimulation is gaining attention. The procedure involves placing small electrical leads in the epidural space of the upper spinal cord, where they deliver electrical pulses that interfere with pain signals before they reach the brain. An estimated 34,000 spinal cord stimulation procedures are performed worldwide each year for various pain conditions.
A narrative review of 7 case reports and 4 retrospective studies found that trigeminal neuralgia patients consistently achieved greater than 50% pain relief after permanent electrode placement. Complications were rare across all the studies reviewed. Perhaps most notably, most patients who responded well were able to significantly reduce or completely stop their oral pain medications, eliminating the side effects that often impair daily life.
Radiofrequency Procedures: Pulsed vs. Continuous
Radiofrequency treatments use heat applied through a needle to disrupt pain signals from the trigeminal nerve. The traditional approach, continuous radiofrequency, heats the nerve enough to damage the pain-transmitting fibers. The newer alternative, pulsed radiofrequency, delivers brief bursts of energy at lower temperatures, aiming to modulate the nerve without destroying it.
A retrospective study comparing the two found similar long-term outcomes: 75% of patients in both groups maintained more than 50% pain improvement over the long term. The critical difference was in side effects. Continuous radiofrequency caused facial numbness in virtually all patients, corneal sensitivity loss in about 6%, and one case of eye muscle weakness. Pulsed radiofrequency caused facial numbness in only about 12% of patients, with no corneal or eye movement complications.
For patients willing to accept some numbness in exchange for reliable pain control, continuous radiofrequency remains effective. Pulsed radiofrequency offers a lower complication rate and is increasingly considered a first-line interventional option, particularly for patients with pain in the upper face where corneal sensation is at risk.
How New Treatments Compare to Surgery
Microvascular decompression (MVD) remains the gold standard surgical treatment, and new five-year prospective data confirms why. At the five-year mark, 59% of MVD patients were completely pain-free without any medication, compared to just 19% of patients managed with drugs alone. Only 23% of surgical patients were still taking medication at five years, versus 62% in the medical group.
The newer treatments described above are not replacing MVD but are filling important gaps. They offer options for people whose pain doesn’t respond to first-line medications, who aren’t surgical candidates due to age or other health conditions, or who experience pain recurrence after surgery. The most significant shift in the treatment landscape is that patients now have several distinct mechanisms of action to try before resorting to, or after exhausting, more invasive approaches. A sodium channel blocker, a glutamate receptor blocker, a CGRP inhibitor, botulinum toxin, and neuromodulation each work through different pathways, which means failure with one doesn’t predict failure with another.